Haisco Pharmaceutical Group Co. Ltd. has disclosed new tetrahydrofuran derivatives acting as sodium channel protein type 10 subunit alpha (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Ono Pharmaceutical Co. Ltd. has patented tricyclic prostaglandin E2 receptor EP3 subtype (PTGER3; EP3) agonists potentially useful for the treatment of renal diseases.
Work at Reactive Biosciences Inc. has led to the discovery of new phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
A D3 Bio (Wuxi) Co. Ltd. patent describes heterocyclic-substituted pyrimidopyran compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Rowan University, Pennsylvania State University, and affiliated organizations presented preclinical data for the selective Mcl-1 inhibitor, KS-18, in models of multiple myeloma (MM).
Insitro Inc. has signed three strategic agreements with Eli Lilly & Co. focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by Insitro using its artificial intelligence/machine learning-based platform.
The identification of non-toxic targets for the treatment of metabolic disorders would allow the development of therapies for the harmful effects of impaired metabolism of reactive aldehydes, among others, which is challenging for drug development due to short half-life and lack of tissue specificity.
Researchers from Rhodes University and collaborators identified MMV-1645152 after screening the Medicines for Malaria Venture (MMV) pandemic response box for non-cytotoxic inhibitors of Kaposi's sarcoma-associated herpesvirus (KSHV) replication.
RSS
